• Yajia Zhang, Sethuramasundaram Pitchiaya, Marcin Cieślik, Yashar S Niknafs, Jean C-Y Tien, Yasuyuki Hosono, Matthew K Iyer, Sahr Yazdani, Shruthi Subramaniam, Sudhanshu K Shukla, Xia Jiang, Lisha Wang, Tzu-Ying Liu, Michael Uhl, Alexander R Gawronski, Yuanyuan Qiao, Lanbo Xiao, Saravana M Dhanasekaran, Kristin M Juckette, Lakshmi P Kunju, Xuhong Cao, Utsav Patel, Mona Batish, Girish C Shukla, Michelle T Paulsen, Mats Ljungman, Hui Jiang, Rohit Mehra, Rolf Backofen, Cenk S Sahinalp, Susan M Freier, Andrew T Watt, Shuling Guo, John T Wei, Felix Y Feng, Rohit Malik, and Arul M Chinnaiyan.
• Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
• Nat. Genet. 2018 Jun 1; 50 (6): 814-824.

AbstractThe androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.

25 keywords...

hide…